AEGiS-APPJ: Estimating Risks and Benefits in AIDS Vaccine and Drug Trials AIDS & Public Policy JournalImportant note: Information in this article was accurate in 1990. The state of the art may have changed since the publication date.
Click here to return to Associated Press main menu
DonateNow
Print this Article


Estimating Risks and Benefits in AIDS Vaccine and Drug Trials

AIDS & Public Policy Journal 5, no. 4 (Winter 1990): 186-88
Elton Kessel

The author offers a general guideline for estimating the risks and benefits of clinical trials of drugs and vaccines in AIDS research and describes strategic considerations for the development effort in order to initiate a dialogue on this subject.
901215
APPJ905408

Copyright © 1990 - AIDS & Public PolicyJournal. Reproduction of this article (other than one copy for personal reference) must be cleared through the APPJ Permissions Desk.

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, Bridgestone/Firestone Charitable Trust, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 1990. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1986, 1990. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .